Indonesia Pharmaceutical Market will be led by Growing Generic Drugs and Bio-pharmaceutical Market: Ken Research - PowerPoint PPT Presentation

About This Presentation

Indonesia Pharmaceutical Market will be led by Growing Generic Drugs and Bio-pharmaceutical Market: Ken Research


Indonesia Pharmaceutical market has registered an increase in the revenue at a CAGR of ~% from USD ~ billion in 2012 to USD ~ billion in 2017. For more information on the research report, refer to below link: – PowerPoint PPT presentation

Number of Views:310


Transcript and Presenter's Notes

Title: Indonesia Pharmaceutical Market will be led by Growing Generic Drugs and Bio-pharmaceutical Market: Ken Research

Indonesia Pharmaceutical Market will be led by
Growing Generic Drugs and Bio-pharmaceutical
Market Ken Research
Expansion of product portfolio by major
pharmaceutical companies and increase in demand
for generic drugs were the key factors driving
growth in Indonesia pharmaceutical Market. The
report titled Indonesia Pharmaceutical Market
Outlook to 2022 - By Therapeutic Segment
(Anti-Infectives, Gastrointestinal and
Metabolism, Cardiovascular System, Central
Nervous System, Respiratory, Musculoskeletal,
Dermatology, Genitourinary and Hormones, Blood,
Oncology), By Domestic and International Players,
By Generic and Patent Drugs, By OTC
Prescription Drugs, By Region by Ken Research
suggested a growth at a CAGR of 10.0 in revenue
in Indonesia Pharmaceutical Market by 2022.
  • Indonesia healthcare market has observed a
    favorable growth in the last 5 years. The market
    is still under penetrated especially in the tier
    2 areas in Indonesia as of 2017.
  • The launch and execution of JKN scheme by the
    government has led to surge in demand for primary
    healthcare facilities and increased generic drug
    sale. The market has underscored various
    deregulation programs which has stimulated
    foreign investment in the industry.
  • Indonesia Pharmaceutical market is dominated by
    domestic players which controlled majority of the
    market in 2017. Recent favorable government
    regulations have facilitated the entry of foreign
    players in the space. There are 206
    pharmaceutical companies (182 domestic and 24
    international companies) located in Indonesia.
  • The market is driven by deregulation in FDI
    regulations in pharmaceutical and favorable
    government policies leading to increase

  • sale of generic drugs. Increased investment in
    innovation of new drugs with higher margin led to
    increased profitability of pharmaceutical
    companies. Expansion of major companies through
    mergers, acquisitions and alliances has enabled
    companies to manufacture high end medicines and
    pharmaceutical products.
  • The local companies largely focus on generic
    drugs manufacturing that are dependent on
    imported active pharmaceutical ingredients (API),
    mainly from China and India.
  • As Jaminan Kesehatan Nasional (JKN) has
    prioritized the use of generic drugs, the demand
    for unbranded generic drugs has grown as
    Indonesians increasingly rely on generic drugs.
    This has augmented the domestic players sales.
    But at the same time, the market has also
    witnessed an increase in number of new players
    which has driven down the margins. Since the
    product portfolio of majority domestic
    pharmaceutical companies is dominated by generic
    drugs, the sales

  • have gone up since 2014. Moreover, the prices of
    generic drugs are regulated and consistent across
    Indonesia whereas the prices increase by 10 for
    branded drugs annually. Domestic players have
    witnessed success in rural areas of Indonesia.
    Due to inaccessibility and language barrier
    existing in the rural areas, the domestic players
    have been better able to bridge the gap as
    compared to international players. The domestic
    players have also dominated the Over the Counter
    drugs which are driven by the increasing self
    medication behavior of the population. Domestic
    players dominate the Anti-Infectives,
    Gastrointestinal and metabolism and respiratory
    therapeutic segments.
  • Indonesia biopharmaceutical industry is in the
    nascent stage. There is a strong interest from
    research-based global biopharma companies to
    conduct clinical research in Indonesia because of
    the large concentrated patient populations and
    disease profiles. Furthermore, as the industry
    intends to move towards self sufficiency,

government released the 11th economic stimulus
package with the aim of boosting the domestic
production of medicines' raw materials,
particularly for five product categories namely
biotechnology, vaccines, herbal extracts, active
pharmaceutical ingredients and medical
devices. In order to tap the existing potential,
large domestic pharmaceutical companies have tied
up with international players to manufacture
biopharmaceutical products for the treatment of
chronic diseases such as cancer, kidney failure
and others. ProBioGen AG, a CDMO based in
Germany, and Bio Farma, a state-owned vaccine
manufacturer in Indonesia, has signed an
agreement to develop a biosimilar to the
monoclonal antibody (mAb) trastuzumab for cancer
treatment that will be produced in Indonesia.
Kalbe Farma has also launched biosimilar version
of insulin in Indonesia to treat diabetes
mellitus which is 38 cheaper than the existing
insulin. Biosimilars are cheaper imitations of
drugs known as biologics. Kalbe Farma set up its
biological drug factory, PT Kalbio Global Medika
in Cikarang, Bekasi, with an investment value
that ranges between USD 30 to USD 35 million. The
factory is built under the joint venture between
Kalbe and a South Korean pharmaceutical company
Genexine Inc, PT Kalbe-Genexine Biologics Key
Topics Covered in the Report Indonesia Dietary
Vitamin Supplements Market Pharmaceutical Market
Size Indonesia Indonesia Vaccine Market Indonesia
Pharmaceutical Regulations Number of
Pharmaceutical Companies Indonesia
Indonesia Pharmaceutical Market Players Obese
Population Indonesia Generic Drug Market Size
Indonesia Number of Healthcare Centers in
Indonesia Budget Allocation on Healthcare
Indonesia Healthcare Spending Indonesia Vitamin
and Dietary Supplement Market Indonesia For more
information on the research report, refer to
below link https//
43542-91.html Related Reports by Ken
Research https//
html Contact Ken Research Ankur Gupta, Head
Marketing Communications
(No Transcript)
Write a Comment
User Comments (0)